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HIV is a rapidly fatal disease in resource-poor environments
where access to antiretroviral (ARV) therapy is limited. Despite
the increasing availability of ARV therapy, the epidemic
continues to grow especially among women of child-bearing
age and children. The appropriate use of ARVs requires careful
consideration of each drug's disposition kinetics, as well as the
impact on the agent of pharmacokinetic and pharma-
codynamic developmental changes occurring across the
paediatric age continuum. Drug absorption may be altered by
limited gastric acid and lipase secretion in infants. Dietary
differences and feeding patterns may also affect drug
absorption. Lower plasma protein levels and higher body water
content in infants can modify drug disposition. Altered
elimination of ARVs is seen both for renal and hepatic routes
of drug removal. While reduced in infants, renal and hepatic
drug elimination increase over the first 2 years of life,
attaining more rapid elimination than in adults. However, the
precise pattern of maturation varies among the metabolic
enzymes responsible for ARV biotransformation. In addition to
these pharmacokinetic differences, formulation limitations
impact on delivery of ARV therapy in the paediatric
population. Liquid forms are not available for many ARVs, and
when they are available they may require refrigeration, lack
stability data in hot climates or require large storage areas.
Even for solid oral dosage forms, the breaking, crushing and
mixing of adult formulations with food or liquids to
administer ARVs to children may affect their bioavailability.
Altered ARV disposition is most pronounced in infancy. Given
the success of antepartum, peripartum and postnatal ARVs to
limit mother-to-child transmission (MTCT), these drugs are
being used in a large number of newborns. Smaller doses of
zidovudine, lamivudine and nevirapine (NVP) have been used
to take into account the reduced elimination. In general these
have been well tolerated in infants. HIV resistance following
single-dose NVP therapy may be the result of its long half-life
and raises concerns regarding future therapy options in both
the mother and infant. Tenofovir is currently being investi-
gated as a potential alternative short-course agent for
prevention of MTCT. Infants may also receive meaningful ARV
exposure as a result of depressed elimination capacity and via
ingestion of breastmilk from mothers receiving therapy. 
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
(NRTIs)
NRTIs are synthetic analogues of naturally occurring 
nucleosides used by cells for DNA replication. These agents
preferentially target the HIV-1 reverse transcriptase enzyme,
which is responsible for transcribing viral RNA into viral DNA
for eventual integration into the host's cellular DNA. For
activity, nucleosides require intracellular phosphorylation into
the active nucleotide moiety. It is the intracellular rather than
serum concentrations of these agents that more closely reflect
their antiviral potency. Longer intracellular half-lives of some
nucleosides allow for once-daily dosing and easier adherence.
Some adverse effects of NRTIs are probably caused by
impairing DNA replication, affecting mitochondrial function.
The stavudine and didanosine combination should be avoided
because maternal deaths have occurred from lactic acidosis
and/or hepatotoxicity (Table I).
In general, the NRTIs share similar pharmacokinetics (Table II).
In general, these agents have good bioavailability and can be
given without regard to food. Didanosine, which is acid labile
and co-formulated with antacids, is the exception with low
bioavailability that is improved when given without food. The
NRTIs have limited protein binding and distribute widely into
tissues, including the placenta, cerebrospinal fluid, and breast-
milk. None undergo extensive liver metabolism via the
cytochrome P450 system (CYP450) and all are either renally
eliminated or metabolised by other hepatic enzymes.
Therefore, drug interactions via the CYP450 system do not
occur with NRTIs, although other pharmacokinetic
interactions do occur (e.g. higher didanosine concentrations
with tenofovir). Zidovudine, didanosine, stavudine, lamivudine
and abacavir exhibit very rapid elimination from plasma. All
are available in liquid formulations. 
ZIDOVUDINE
Zidovudine is a thymidine analogue and was the first ARV
agent. Following absorption, zidovudine undergoes
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Drug Dose Major toxicities Other comments
Nucleoside/tide reverse transcriptase inhibitors
Abacavir (ABC, Ziagen) < 3 mo.: 8 mg/kg bid is Nausea, vomiting, fever, Syrup is well tolerated or tablet 
300 mg tab under investigation headache, diarrhoea, rash,  may be crushed
20 mg/ml sol > 3 mo.: 8 mg/kg (max 300 mg) bid anorexia, lactic acidosis, hepatic Can be given with food
Adolescents: 300 mg bid steatosis, hypersensitivity  WARN PARENTS ABOUT 
reaction (in 2 - 5% can be FATAL), HYPERSENSITIVITY REACTION
pancreatitis, hepatitis, fatigue, Discontinue ABC permanently 
hypertriglyceridaemia and never rechallenge if 
hypersensitivity reaction occurs
Didanosine, dideoxyinosine < 90 d: 50 mg/m2 12-hrly GI disturbances, peripheral Suspension must be refrigerated;
(ddI, Videx) > 90 d: 120 (range 90 - 150) mg/m2 neuropathy, electrolyte stable for 30 days; shake well 
25, 50, 100, 150, 200 mg 12-hrly disturbances, hyperuricaemia, before use
chew tab Adolescents: lactic acidosis, hepatic steatosis, Administer dose 1 h before or
100, 167, 250 mg pwdr pkt < 60 kg: 125 mg bid OR pancreatitis, diarrhoea, retinal 2 h after food; may be less 
10 mg/ml susp 250 mg qd (EC form) depigmentation important in children
125, 200, 250, 400 mg > 60 kg: 200 mg bid OR Enteric-coated beadlets in
EC tab 400 mg qd (EC form) capsules may be opened and 
sprinkled on small amount of 
food
Lamivudine (3TC, Epivir) < 30 d: 2 mg/kg bid† Headache, fatigue, GI Can be given with food
150, 300  mg tab ≥ 30 d: 4 mg/kg bid† disturbances, pain, pancreatitis, Well tolerated
10 mg/ml sol Adolescents: peripheral neuropathy, Store solution at room 
< 50 kg: 2 mg/kg neutropenia, hepatitis, hepatic temperature and use within 
> 50 kg: 150 mg bid OR 300 mg qd steatosis, lactic acidosis 1 month of opening
†not FDA approved under 3 mo.
Stavudine (d4T, Zerit, ≤ 6 mo.: Under evaluation Headache, GI disturbances, rash, Large volume of solution
Zerit XR) (PACTG protocol 332) peripheral neuropathy, Refrigerate solution; stable for 
15, 20, 30, 40 mg cap ≥ 6 mo.: 1 mg/kg 12-hrly up to pancreatitis, lactic acidosis, 30 days
75, 100 mg XR cap 30 mg hepatic steatosis Store in glass bottles
1 mg/ml sol Adolescents: Shake well before administration
30 - 60 kg: 30 mg bid or 75 mg XR qd Capsules may be opened and 
> 60 kg: 40 mg bid or 100 mg XR bid mixed with small amount of 
food; stable in solution for 
24 h if refrigerated
Do not use with AZT 
(antagonistic)
Tenofovir disoproxil fumarate No neonatal or paediatric data, but GI disturbances, lactic acidosis, Tablet can be crushed and mixed
(TDF, Viread) phase I study in children ≥ 4 yrs hepatic steatosis, bone and in water or juice
300 mg tab currently enrolling (NCI protocol renal toxicity in animals, not seen
020006) in adult humans but experience
≥ 18 yrs: 300 mg qd limited
Zidovudine (AZT, ZDV, Premature infants < 34 wks Anaemia, neutropenia, Large volume of syrup not well
Retrovir) 300 mg tab gestational age: 1.5 mg/kg IV 12-hrly headache, myopathy, myositis, tolerated in older children
100 mg cap or 2 mg/kg PO 12-hrly, increased to hepatitis, lactic acidosis, Requires storage in glass jars; 
10 mg/ml syrup 8-hrly at 2 wks post-conceptional hepatomegaly and hepatic light-sensitive
10 mg/ml injectable age if ≥ 30 wks or at 4 wks post- steatosis Can be given with food
conceptional age if < 30 wks Do not use with d4T 
gestational age (antagonistic)
Term infants < 90 d: 2 mg/kg 
PO 6-hrly or 1.5 mg/kg IV 6-hrly
≥ 90 d: 160 mg/m2 8-hrly
(range 90 - 180 6 - 8-hrly) or 
120 mg/m2 IV 6-hrly or 20 mg/m2/h
continuous IV 
Some experts recommend 180 mg/m2
12-hrly when used in combination 
with other ARV drugs, but data are 
limited
Adolescents: 200 mg tid or 
300 mg bid
TABLE I. AVAILABLE ANTIRETROVIRAL THERAPEUTIC AGENTS*
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TABLE I. AVAILABLE ANTIRETROVIRAL THERAPEUTIC AGENTS* (CONTINUED)
*All doses are oral unless otherwise noted. Adapted from NIH Guidelines (http://www.aidsinfo.nih.gov), manufacturer prescribing information, and WHO Guidelines for Scaling Up
Antiretroviral Therapy.
Drug Dose Major toxicities Other comments
Non-nucleoside reverse transcriptase inhibitors
Efavirenz (EFV, Sustiva) 10 - < 15 kg: 200 mg at night (not Dizziness, dream and sleep Capsules may be opened and 
50, 100, 200 mg cap FDA approved under 3 yrs) disturbances, agitation, feeling added to food, but have a 
600 mg tab 15 - < 20 kg: 250 mg at night ‘disconnected’, amnesia, peppery taste that can be 
20 - < 25 kg: 300 mg at night impaired concentration, disguised when mixed with 
25 - < 32.5 kg: 350 mg at night hallucinations, rash, sweet foods or jam
32.5 - < 40 kg: 400 mg at night teratogenesis in primates Can be given with food, but
> 40 kg: 600 mg at night (avoid in pregnancy) avoid high-fat meals 
Administer at bedtime
preferably to reduce central 
nervous system side-effects 
especially in the first 2 weeks
Drug interactions 
Nevirapine (NVP, Viramune) ≤ 2 mo.: 5 mg/kg or 120 mg/m2 Skin rash (including Stevens- Can be given with food
10 mg/ml susp qd x 14 d, then 120 mg/m2 12-hrly Johnson), fever, nausea, Store suspension at room
200 mg tab x 14 d, then 200 mg/m2 12-hrly headache, elevated hepatic temp. and shake well before use
(under investigation in PACTG transaminases, hepatitis (can be WARN PARENTS ABOUT RASH
protocol 356) severe or fatal), hypersensitivity Do not escalate dose if rash
> 2 mo.: 120 mg/m2 qd x 14 d, then reactions occurs (for mild-moderate rash,
120 - 200 mg/m2 (maximum 200 mg) hold drug until rash clears, then
12-hrly OR 7 mg/kg 12-hrly if < 8 yrs restart dosing from beginning 
and 4 mg/kg 12-hrly if > 8 yrs of escalation); if severe rash, 
Adolescents: discontinue drug
200 mg qd x 14 d, then 200 mg Increase NVP dose by about




Lopinavir/ritonavir (LPV/RTV, < 6 mo.: 300 mg/m2 LPV/75 mg/m2 Diarrhoea, headache, asthenia, Oral solution and capsules 
LPV/r, Kaletra) RTV is under investigation (PACTG and nausea and vomiting, should be preferably refrigerated;
80 mg LPV/20 mg RTV per protocol 1030) but dose escalation hyperlipidaemia, however can store at room 
ml sol may be necessary hypercholesterolaemia, rash in temperature (up to 25°C) for 
133.3 mg LPV/33.3 mg RTV ≥ 6 mo. and 7 - < 15 kg: patients receiving LPV/r with 2 months
per cap 12/3 mg/kg bid other ARV drugs, spontaneous Liquid formulation has alcohol, 
15 - 40 kg: 10/2.5 mg/kg bid  bleeding episodes in low volume, but bitter taste
> 40 kg: 400/100 bid haemophiliacs, pancreatitis, Capsules are large, tablet form 
OR (for all weights ≥ 7 kg and hyperglycaemia, ketoacidosis, under investigation
age ≥ 6 mo.) 230/57.5 mg/m2 diabetes, and hepatitis Take with food
bid (max. 400/100 mg) Numerous drug interactions
With efavirenz or nevirapine:
< 6 mo.: No data
≥ 6 mo. and 7 - < 15 kg:
13/3.25 mg/kg bid
15 - 50 kg: 11/2.75 mg/kg bid
≥ 50 kg: 533/133 mg bid
OR (for all weights ≥ 7 kg and age 
≥ 6 mo.) 300/75 mg/m2 bid (max. 
533/133 mg)
Nelfinavir (NFV, Viracept) Newborn: 40 mg/kg bid is under Diarrhoea, asthenia, abdominal Powder is sweet, faintly bitter, 
200 mg/tsp pwdr investigation (PACTG protocol 353)‡ pain, rash, and exacerbation of but gritty and hard to dissolve;
50 mg per one level gram 2 - 6 yrs: 20 - 30 mg/kg tid is the chronic liver disease, reconstitute immediately before 
scoop FDA-approved dose, but doses up to spontaneous bleeding episodes administration in water, milk, 
250, 625 mg tabs 45 mg/kg tid are routinely used in haemophiliacs, hyperglycaemia, formula, pudding, etc.; avoid
> 6 yrs: 55 mg/kg bid ketoacidosis, and diabetes mixing with acidic food or juice
Adolescents: (increases bitter taste)
750 mg tid OR 1 250 mg bid OR Crushed tablets may be 
1 500 mg bid under study preferred (even for infants) 
‡not FDA approved under 2 yrs given difficulties with powder 
formulation if appropriate dose 
can be given
Store powder and tablets at 
room temperature
Take with food. 
Drug interactions
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glucuronidation to zidovudine-glucuronide, which is then
excreted renally. Zidovudine pharmacokinetics have been
studied in a wide range of paediatric populations from
preterm infants to adolescents, demonstrating rapid increases
in clearance during the first few weeks of life with smaller
increases throughout the first 2 years of life. Zidovudine has
the shortest half-life of the NRTIs and requires at least twice-
daily administration. The initial dose of 8 mg/kg/d in divided
doses is increased to 160 mg/m2 8-hourly at 6 - 12 weeks of
age. Bone marrow suppression, presenting as anaemia and
neutropenia, are the most prominent adverse effects and are
more frequently seen with higher zidovudine concentrations.
LAMIVUDINE
Lamivudine is a cytidine analogue that is widely used in
children and adults. In general it is one of the most well-
tolerated agents in this class. Lamivudine undergoes minor
liver metabolism to the inactive trans-sulphoxide metabolite.
The primary route of elimination is renal, which is initially
immature in the neonate and requires reduced dosing in this
population. The primary route of elimination is renal, which is
initially immature in the neonate, and lamivudine requires
reduced dosing in this population.1,2
STAVUDINE
Stavudine is a widely available thymidine analogue, but its
pharmacokinetic fate has not been fully elucidated. About
60% of the drug is eliminated via endogenous pathways while
40% is renally eliminated via filtration and active tubular
secretion.3 Decreased renal function in the neonate suggests
that a reduced dosage may be needed initially. The dosage of
stavudine is based on whether the child weighs less than or
more than 30 kg. Dosages of 0.5 - 1 mg/kg/d across a wide age
range in children produced equivalent exposure to that
achieved in adults.4 Coadministration of stavudine with
zidovudine is not recommended owing to competitive
intracellular phosphorylation and thus potential loss of
activity. Its combination with didanosine is also to be avoided
owing to increased toxicities. The paediatric oral solution
requires refrigeration, given that in one study significant loss
Primary  Food 
elimination CL/F effect on Protein
Drug Age group route (l/h/kg) T12 (h) absorption binding Reference
Zidovudine Premature neonates 4 - 7 d Hepatic: UGT > Minimal Low Capparelli21
< 30 wks GA: Renal 0.09
> 30 wks GA: 0.13
Premature neonates 4 - 8 d 0.14 ± 0.35 7.3 ± 1.9
Premature neonates 10 - 25 d 0.26 ± 0.35 4.4 ± 1.5
Term neonates 1 - 13 d 0.65 ± 0.29 3.1 Hoody20
Infants & children 6 mo. - 12 yrs 1.8 1.5
Lamivudine Neonates 7 d Renal 0.40 6 None Low Hoody20
Children 5 mo. - 17 yrs 0.77 2.1
Stavudine Children 5 wks - 15 yrs Renal 0.83 ± 0.26 0.96 None Low Package 
insert3
Didanosine Infants ≤ 120 d Renal & 57 ± 30 (l/h/m2) Food Low Kovacs7
Children 3 mo. - 18 yrs Hepatic: PNP 152.5 ± 81.7 0.93 ± 0.43 Stevens6
(l/h/m2)
Abacavir Children 3 mo. - 13 yrs Hepatic: ADH 0.95 1.28 None Moderate Hoody20
& UGT
Nevirapine Neonates (single dose) Hepatic: CYP3A, 0.033 37 None Moderate Mirochnick22
Infants & children 1 mo. - 16 yrs CYP2B6 0.10 + 0.06 Capparelli23
Efavirenz Children 4 - 16 yrs Hepatic: CYP3A, 0.19 Avoid high- High Hoody20
CYP2B6 fat meals
Nelfinavir Infants 2 - 8.5 mo. Hepatic: CYP3A, 4.2 2.6 Food (high High Litalien24
Children 2 - 14 yrs CYP2C19 1.5 fat) Hoody20
Lopinavir/ Children 6 mo. - 12 yrs Hepatic: CYP3A 2.57 ± 5.25 7.6 ± 5.1 Food High Saez-
ritonavir (l/h/m2) Llorens15
Tenofovir Children 6 - 16 yrs Renal 32 ± 16.3 12.5 Food  Low Hazra25
(l/h/m2)
* All values are means ± standard deviation.
CYP = cytochrome; UGT = uridine glucuronyl transferase; ADH = alcohol dehydrogenase; PNP = purine nucleoside phosphorylase.
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of stability was observed after 4 weeks at 25°C.5 Instead,
capsules may be opened and mixed with a small amount of
food or liquid before administration. 
DIDANOSINE
Didanosine is an inosine analogue that requires intracellular
phosphorylation for activity in resting cells. It has a long
intracellular half-life of 25 - 40 hours, which allows for once-
daily dosing. Didanosine is rapidly degraded in acidic media
necessitating coadministration with buffering agents or
antacids for optimal absorption. Didanosine should therefore
ideally be given without food or 2 hours after a meal for
optimal absorption. However, this may be impractical for
young children who feed frequently. A study of didanosine
with and without food in children showed modest reductions
in peak concentrations.6 It is eliminated through metabolism
similar to that of endogenous purines as well as renal
pathways.
Infants younger than 7 months of age have lower didanosine
clearance than older children. As a result of reduced
clearance, infants 2 weeks - 4 months of age may benefit from
a smaller dosage initially to avoid risk of didanosine toxicity.7,8
Didanosine should not be given with stavudine or zalcitabine
to avoid overlapping toxicities of peripheral neuropathy and
pancreatitis. The liquid formulation needs to be prepared with
antacid. After reconstitution, the oral solution is stable at
temperatures up to 35°C for 8 weeks.5
OTHER NUCLEOSIDES
Other NRTI members that are not generally available in Africa
include abacavir, emtricitabine, and the nucleotide analogue,
tenofovir. Briefly, emtricitabine is a cytidine nucleoside
analogous to lamivudine with a longer plasma half-life.
Abacavir is a guanosine analogue with synergy to zidovudine
and lamivudine but clinically low activity in highly treatment-
experienced patients. While generally well tolerated, a
potentially fatal hypersensitivity reaction can occur in up to
5% of children.9 Tenofovir is an acyclic nucleotide prodrug
that is converted into the active triphosphate intracellularly.
Its ability to produce rapid reduction in viral replication has
generated interest in it as a potential therapy to prevent MTCT.
It can cause nephrotoxicity and it also has drug interactions
with didanosine, lopinavir and atazanavir.10
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE 
INHIBITORS (NNRTIs)
NNRTIs inhibit the HIV-1 reverse transcriptase at a non-
competitive site on the enzyme and, unlike the NRTIs, do not
require intracellular activation. NNRTIs are potent agents, but
the entire class can be rendered inactive by a single resistance
mutation in the RT gene. NNRTIs are lipophilic, moderately to
highly protein bound, and widely distributed. They undergo
hepatic metabolism via CYP2B6 and CYP3A4 inducing their
own metabolism. Hepatotoxicity is a class adverse effect that
requires routine liver function monitoring.
NEVIRAPINE
Nevirapine has been used extensively in neonates and
children. It is well absorbed and does not require food for
optimal absorption. Nevirapine is highly lipophilic and widely
distributed including crossing the placenta. It is also a CYP3A4
inducer that can increase the clearance of other
coadministered CYP3A4 substrates, including protease
inhibitors. Nevirapine oral clearance is age-dependent. In
neonates the half-life of nevirapine is prolonged with
clearance doubling over the first month of life.11 This long
half-life allows HIV-suppressive concentrations to be
maintained for 2 weeks with a single dose to the mother
followed by a single dose to infants at 4 - 5 days of life. Older
infants and children appear to have greater nevirapine
clearance than adults.12 The nevirapine dose is given twice as
frequently after the first 2 weeks of therapy to account for the
autoinduction of its metabolism.
Nevirapine therapy can cause hepatotoxicity and severe
hypersensitivity reactions. Hepatic dysfunction usually occurs
within the first few months of therapy, can be fatal and occurs
more frequently in adults with elevated baseline liver
transaminases, hepatitis B or C coinfection, and higher CD4
counts. Women are also at a higher risk for nevirapine-
induced hepatotoxicity; pregnant women with CD4 counts
> 250 cells/µl have a 12-fold greater risk for hepatotoxicity.13
Nevirapine can also cause severe, life-threatening skin
reactions, some resulting in death, including cases of Stevens-
Johnson syndrome and toxic epidermal necrolysis. 
Paediatric dosing for nevirapine has been based on both body
surface area (BSA) and milligram per kilogram methods. The
weight-based dosing results in wider variability in exposure
than the BSA dosing. Weight-band dosing, linked to available
formulation sizes, has been developed to match the BSA
dosing and improve exposure without calculating BSA.
EFAVIRENZ
Efavirenz has been used extensively in children over 3 years of
age with excellent success. In older children it is well absorbed
and can be given once daily owing to its long half-life.
Pharmacokinetic data are sparse in children under 3 years of
age, but initial studies suggest that larger doses of the
suspension may be needed. If given with rifampicin, a modest
increase in the dose of efavirenz is suggested. Frequently in
adults, and in up to 14% of children, efavirenz causes central
nervous system side-effects. Bedtime administration of
efavirenz is advocated to possibly decrease the impact of side-
effects.14 It can be given without regard to food, although
high-fat meals are discouraged in adults to avoid an increase
in adverse effects from increased absorption. 
PROTEASE INHIBITORS (Pls)
PIs block the HIV-1 protease enzyme, which results in the
formation of immature viral proteins incapable of
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transmission to non-infected host cells. Unlike the NNRTIs,
resistance to PIs requires multiple mutations to render this
class useless. 
Only two PIs are likely to be encountered in resource-limited
environments. Most PIs do not have adequate paediatric
formulations or have a high pill burden, and need at least
twice-daily dosing. All members of this class have variable oral
absorption which is dependent on dosing in the presence or
absence of food, and even on the composition of food intake.
They exhibit incomplete and variable absorption, are highly
protein bound and achieve only limited penetration into the
CSF and across the placenta. They undergo extensive phase I
oxidative metabolism primarily via CYP3A4. PIs are well-
known substrates of CYP3A4 and some are also potent
inhibitors of this system. This results in a large number of drug
interactions with other ARVs and antituberculosis agents. 
Drug-drug interactions with PIs are well recognised in adults
and probably occur in children as well. Fortunately PIs can be
combined to produce greater potency and durability, often
taking advantage of positive pharmacokinetic drug inter-
actions, without concern for the antagonist drug activity that
plagues members of the NRTI class. A disadvantage of PIs is a
higher incidence of gastrointestinal adverse effects that can
negatively affect drug tolerability, adherence and absorption.
Increasingly, PIs have also been linked to metabolic
complications such as glucose intolerance, insulin resistance,
hyperlipidaemia and lipodystrophy. The impact of these effects
on paediatric growth and development is unknown.
LOPINAVIR/RITONAVIR
Lopinavir/ritonavir is a PI co-formulated with a small dose of
a pharmacokinetic enhancing agent, ritonavir. Ritonavir is a
potent inhibitor of CYP3A4, which increases the lopinavir
plasma exposure and half-life of lopinavir allowing for twice-
daily administration. Food enhances lopinavir absorption.
Lopinavir is highly protein bound and is hepatically
metabolised with very little renal elimination. In a study of
children between 6 months and 12 years of age, a dose of
230/57.5 mg/m2 or 300/75 mg/m2 twice daily with nevirapine
achieved similar lopinavir exposure to adults.15 Limited data in
younger infants suggest high variability in absorption and
elimination. This variability may make this agent difficult to
use in young infants.16
Lopinavir is available in a bitter paediatric oral solution that is
taken with food for optimal absorption. The oral solution also
contains 42% alcohol and requires refrigeration. Exposure to
excessive heat is discouraged, and if left at room temperature
(25°C) the solution or capsules must be used within 2 months.
While both formulations appear to retain potency for brief
periods of time at temperatures up to 45°C, the current gelcap
formulation fuses together making them unusable.17
NELFINAVIR
Nelfinavir was the first PI well studied in paediatric patients.
High-fat meals enhance absorption and large doses are
needed in infants to achieve adequate exposure. Most
practitioners crush tablets for young children rather than
administer the powder formulation, owing to inconsistent
absorption of the powder. Neither formulation requires
refrigeration. Nelfinavir, however, is poorly absorbed in the
absence of food and erratic feeding patterns and changes in
gastrointestinal motility can also dramatically decrease oral
bioavailability. It is metabolised to an M8 active metabolite via
CYP2C19 and is also metabolised by CYP3A. Pharmacokinetic
studies of nelfinavir have demonstrated a rapid oral clearance
in very young children, requiring larger mg/kg daily doses than
adults to attain similar exposure to that in adults.18-20
SUMMARY
Half of the ARV agents available worldwide have paediatric
approval, but many are without ideal paediatric formulations.
Pharmacokinetic differences in paediatric populations require
careful attention to dosing and concomitant therapies.
Importantly, ARV therapy can be limited by short-term and
long-term toxicity and drug interactions.
Low-cost, sustained and consistent access to ARV therapy is
necessary to combat the HIV epidemic. For optimal response
> 90 - 95% adherence to ARVs is required. This requires that
extensive education and support resources be provided in
addition to the ARV medications themselves. Paediatric
patients receiving ARV therapy require ongoing monitoring to
ensure tolerability, dose adjustments with advancing age,
acceptability and therapeutic success. 
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